International Collaborative Gaucher Group (ICGG) Gaucher Registry

Trial Profile

International Collaborative Gaucher Group (ICGG) Gaucher Registry

Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Alglucerase (Primary) ; Imiglucerase (Primary)
  • Indications Gaucher's disease; Gaucher's disease type I
  • Focus Therapeutic Use
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 01 Sep 2017 Results (Data cut off 4 March 2016; n=2069) of an analysis assessing prevalence of severe clinical manifestations in Gaucher disease type 1 (GD1) patients at the time of treatment initiation since alglucerase/imiglucerase approval in USA, published in the American Journal of Hematology
    • 23 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top